Study drug PT886 for gastric and pancreatic adenocarcinoma (PT886X1101)

What is the Purpose of this Study?

We are doing this study to see if the study drug, PT886, with or without chemotherapy and/or pembrolizumab, is a safe and effective option for gastric and pancreatic cancer. We are also trying to find the best dose of the study drug to use.

What is the Condition Being Studied?

Gastric and Pancreatic Adenocarcinoma

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with an advanced or metastatic cancer of the following types:

  • Gastric or gastroesophageal junction adenocarcinoma; OR
  • Pancreatic ductal adenocaricnoma

For more information, contact the study team at dana.a.warren@duke.edu.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Receive infusions of PT886 every 1 to 3 weeks
  • Depending on which arm of the study you are in, you may also get chemotherapy and/or pembrolizumab
  • Have your tumor biopsied
  • Give blood and urine samples
  • Have regular CT or MRI scans

Study Details

Full Title
[PT886X1101] A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and/or the ChecKpoint Inhibitor Pembrolizumab
Principal Investigator
Headshot of Nicholas Christian DeVito
Assistant Professor of Medicine
Protocol Number
IRB: PRO00116720
NCT: NCT05482893
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate